KZIA
$7.53
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel.
Recent News
US Equity Futures Mixed Pre-Bell Monday Despite Oil Sector Surge
Investors revved up oil and oil services shares premarket Monday, but US equity futures were mixed f
Traders Await Nvidia Earnings, Fed Minutes, Driving Narrow Premarket Gains for US Equity Futures
US equity futures posted narrow gains ahead of Wednesday's opening bell as traders looked ahead to N
Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps
Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab), and standard chemotherapy after completing Cycle 1 (21 days) of dosing. The patient, a 61-year-old woman with metastatic triple-negative breast cancer localized to the left upper lobe of the lung, has shown highly encouraging preliminary results at 21 days, with a >50% reduction
Kazia Therapeutics First Half 2025 Earnings: AU$12.29 loss per share (vs AU$18.40 loss in 1H 2024)
Kazia Therapeutics ( NASDAQ:KZIA ) First Half 2025 Results Key Financial Results Revenue: AU$22.3k (up by AU$22.3k from...